FAP and neoplasm: Herein, we demonstrate that combined therapies using radiolabeled FAP-targeting agent 177Lu-FAP-2287, a murine surrogate of 177Lu-FAP-2286, together with PD-1 checkpoint blockade induce tumor inhibition in a FAP expressing MCA205 fibrosarcoma tumor model.